TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 3 · Moderate priorityNCT07018752

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is comparing roginolisib, golcadomide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

roginolisib (DRUG): Roginolisib daily intake | golcadomide (DRUG): Golcadomide daily intake | azacitidine (DRUG): oral 5-azacitidine daily intake

Drugs / treatments
roginolisib, golcadomide, azacitidine
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

NCT07018752

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 1, Phase 2 trial is comparing roginolisib, golcadomide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

roginolisib (DRUG): Roginolisib daily intake | golcadomide (DRUG): Golcadomide daily intake | azacitidine (DRUG): oral 5-azacitidine daily intake

Drugs / treatments: roginolisib, golcadomide, azacitidine

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, open-label

Enrollment target: 49 patients

Primary endpoint: Modified Progression-Free Survival; Maximum Tolerated Dose; Recommended Phase II Dose

Ages: 18 Years to —

Start date: 2025-08-20 | Est. completion: 2030-01

Locations

0 US sites · 20 total

Contact

Clinical Project Manager | platform@lysarc.org | +33 4 72 66 93 33

Sponsor: The Lymphoma Academic Research Organisation (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07018752

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.